CN115947817A - Tumor-related polypeptide and preparation method and application thereof - Google Patents
Tumor-related polypeptide and preparation method and application thereof Download PDFInfo
- Publication number
- CN115947817A CN115947817A CN202310146388.5A CN202310146388A CN115947817A CN 115947817 A CN115947817 A CN 115947817A CN 202310146388 A CN202310146388 A CN 202310146388A CN 115947817 A CN115947817 A CN 115947817A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- sema3a
- truncated protein
- protein
- truncated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 92
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 92
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 92
- 238000002360 preparation method Methods 0.000 title claims description 4
- 206010028980 Neoplasm Diseases 0.000 title abstract description 11
- 102000013008 Semaphorin-3A Human genes 0.000 claims abstract description 64
- 108010090319 Semaphorin-3A Proteins 0.000 claims abstract description 64
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 55
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 54
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 38
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 24
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims abstract description 15
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims abstract description 12
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims abstract description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 12
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 abstract description 8
- 238000011282 treatment Methods 0.000 abstract description 5
- 230000009982 effect on human Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 16
- 229940079593 drug Drugs 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 10
- 206010027476 Metastases Diseases 0.000 description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 description 8
- 230000009401 metastasis Effects 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101100042271 Mus musculus Sema3b gene Proteins 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000030648 nucleus localization Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 1
- 102000014413 Neuregulin Human genes 0.000 description 1
- 108050003475 Neuregulin Proteins 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a polypeptide for inhibiting human ovarian cancer cells, which is derived from a Sema3A truncated protein, wherein the polypeptide derived from the Sema3A truncated protein is coupled with a cell-penetrating peptide to form a cell-penetrating peptide-Sema 3A truncated protein polypeptide; the said polypeptide of truncated protein of Sema3A includes 4 polypeptides, said 4 polypeptides are polypeptide of truncated protein of Sema3A 10, polypeptide of truncated protein of Sema3A 16, polypeptide of truncated protein of Sema3A 20, polypeptide of truncated protein of Sema3A 26 respectively; the amino acid sequences of the Sema3A truncated protein polypeptide 10, the Sema3A truncated protein polypeptide 16, the Sema3A truncated protein polypeptide 20 and the Sema3A truncated protein polypeptide 26 are respectively shown as SEQ ID NO.10, SEQ ID NO.16, SEQ ID NO.20 and SEQ ID NO. 26. The invention screens 4 tumor-related polypeptides on the basis of the Sema3A protein. The polypeptide has good inhibition effect on human ovarian cancer cells after being coupled with the cell-penetrating peptide. Therefore, the polypeptide provides good reference and guidance for subsequent polypeptide treatment of the epithelial ovarian cancer, and has important significance.
Description
Technical Field
The invention belongs to the technical field of biology, and particularly relates to a tumor-related polypeptide, and a preparation method and application thereof.
Background
Ovarian cancer is a malignant tumor of ovarian tumor, and refers to a malignant tumor growing on the ovary, wherein 90% -95% of the malignant tumor is the primary cancer of the ovary, and the other 5% -10% of the malignant tumor is the metastasis of the cancer at other parts to the ovary. Because ovarian cancer lacks symptoms in the early stage, even if the ovarian cancer has symptoms, the ovarian cancer is not specific, and the screening effect is limited, the early diagnosis is difficult, 60 to 70 percent of cases are in the late stage, and the late stage cases have poor curative effect. Therefore, although the incidence rate of ovarian cancer is lower than that of cervical cancer and endometrial cancer which are located at the third position of gynecological malignant tumors, the mortality rate exceeds the sum of the cervical cancer and the endometrial cancer, and the ovarian cancer is located at the first position of gynecological cancer, so that the ovarian cancer is the biggest disease which seriously threatens the health of women.
Epithelial Ovarian Cancer (EOC) is the most common histological type of ovarian cancer, accounting for 50% -70% of ovarian tumors. The disease is hidden, an effective early screening method is lacked, and 76% of patients have been planted in the abdominal cavity, liver parenchyma and/or thoracic cavity and intracranial metastasis (stage III and IV) when finding the disease.
The Sema family is involved in tumor cell proliferation, migration and angiogenesis and plays an important role in tumor invasion and metastasis. Sema3A is the most typical and first-identified neuregulin in the Sema3 family, whose gene is considered to be a candidate Cancer suppressor gene (tamangone l. Emulsifying role of semigenes as major regulatory signals and potential therapeutic targets in Cancer [ J. Cancer Cell,2012,22 (2): 145-152). The low level of Sema3A has been found to be associated with poor prognosis in patients with EOC (JIANG H, QI L, WANG F, et al, secreted sepaphorin 3A expression with a pore promoter secretion in tissues with an epithelial overan carcinosa [ J ]. Int J Mol Med,2015,35 (5): 1374-1380 ], suggesting that Sema3A may be involved in the development and progression of EOC. The research of Wangxiang and the like proves that (Sema 3A participates in epithelial ovarian cancer metastasis by regulating epithelial-mesenchymal transition/matrix metalloproteinase-2), sema3A participates in EOC metastasis by regulating EMT/MMP-2 pathway, and the Sema3A can be used as a biological index for predicting EOC metastasis and prognosis.
Disclosure of Invention
The invention provides a tumor-associated polypeptide on the basis of the existing research, wherein the polypeptide is derived from Sema3A protein, and the function of the polypeptide in EOC (Ethernet over coax).
Therefore, the invention provides a polypeptide for inhibiting human ovarian cancer cells, wherein the polypeptide is derived from a truncated protein of Sema3A, and the polypeptide derived from the truncated protein of Sema3A is coupled with a cell-penetrating peptide to form a cell-penetrating peptide-Sema 3A truncated protein polypeptide; the said polypeptide of truncated protein of Sema3A includes 4 polypeptides, said 4 polypeptides are polypeptide of truncated protein of Sema3A 10, polypeptide of truncated protein of Sema3A 16, polypeptide of truncated protein of Sema3A 20, polypeptide of truncated protein of Sema3A 26 respectively; the amino acid sequences of the Sema3A truncated protein polypeptide 10, the Sema3A truncated protein polypeptide 16, the Sema3A truncated protein polypeptide 20 and the Sema3A truncated protein polypeptide 26 are respectively shown as SEQ ID NO.10, SEQ ID NO.16, SEQ ID NO.20 and SEQ ID NO. 26.
Preferably, the amino acid sequence of the truncated protein of Sema3A according to the invention is shown in SEQ ID NO. 29.
Preferably, the amino acid sequence of the cell-penetrating peptide is YGRKKKRRQRRR.
Preferably, the C-terminus of the cell-penetrating peptide of the invention is coupled to the N-terminus of the polypeptide.
In still another aspect, the invention also provides a medicament for inhibiting human ovarian cancer cells, wherein the medicament comprises any one or any two or any three or four of the polypeptides of the truncated protein of the cell-penetrating peptide-Sema 3A.
Preferably, the total concentration of polypeptides in the medicament of the present invention is 50. Mu.M.
In still another aspect, the invention also provides an application of the polypeptide for inhibiting the human ovarian cancer cells in preparing a medicament for treating epithelial ovarian cancer.
The invention screens 4 tumor-related polypeptides on the basis of the Sema3A protein. The polypeptide has good inhibition effect on human ovarian cancer cells after being coupled with the cell-penetrating peptide. Therefore, the polypeptide provides good reference and guidance for subsequent polypeptide treatment of the epithelial ovarian cancer, and has important significance.
In addition, compared with chemical drugs and protein drugs, the polypeptide drug has the advantages of higher efficiency, higher safety, higher tolerance, higher selectivity and difficult accumulation in vivo, and is one of the important directions for the research of tumor treatment drugs in the future. As shown in table 1.
TABLE 1 comparison of chemical, polypeptide, and protein drugs
Drawings
FIG. 1 prediction of Sema3A protein signal peptide.
FIG. 2 prediction of the remaining sequence of the Sema3A protein (20 amino acids removed from the N-terminus and 45 amino acids removed from the C-terminus). A higher score indicates a higher probability that the location is a disordered region, and 0.5 is used as a boundary for whether the location is a disordered region.
Detailed Description
The present invention is further illustrated by the following specific examples, which are not intended to limit the invention in any way. Reagents, methods and apparatus used in the present invention are conventional in the art unless otherwise indicated. Unless otherwise indicated, reagents and materials used in the following examples are commercially available.
The existing research proves that the Sema3A protein is low expressed in epithelial ovarian cancer, and the research finds that the improvement of the expression of the Sema3A protein can obviously inhibit EOC metastasis. Therefore, on the basis of the prior art, the Sema3A protein is researched and analyzed, the polypeptide of the Sema3A truncated protein is designed, and the polypeptide capable of obviously inhibiting the human ovarian cancer cells is screened from the polypeptide, so that the reference is provided for the treatment of the EOC metastasis.
Example 1: design of Sema3A truncated protein Polypeptides
Sema3A protein (Q14563. SEM3A _ HUMAN) was analyzed. First, the signal peptide was predicted, and the result showed (FIG. 1) that the probability of signal peptide was 98.0%, the type of signal peptide was SP (Sec/SPI), the cleavage site was aa20 to aa21, and the sequence of signal peptide was MGWLTRIVCLFWGVLLTARA.
Nuclear localization signal peptide prediction was performed on Sema3A protein. The result shows that the probability of the signal peptide with the nuclear localization is 90.9%, the position of the signal peptide in the Sema3A protein is aa727-aa762, and the specific sequence is KRDRKQRRQRQRPGHTPGNSNKWKHLQEKNKRNRRTH.
Based on the above results, 20 amino acids (aa 1 to aa20, signal peptide sequence) were removed from the N-terminus and 45 amino acids (aa 727 to aa771, mainly nuclear localization sequence) were removed from the C-terminus of Sema3A protein, and the remaining amino acid sequences were predicted as disordered regions. The results show (FIG. 2) that the probability of about aa650 to aa675 disordered regions is high, and that the remaining 650 amino acid sequences (named as the truncated Sema3A protein, the specific amino acid sequence being shown in SEQ ID NO. 29) were polypeptide-designed by taking into account the removal of the aa651 to aa706 amino acids. 28 Sema3A truncated protein polypeptides were designed and synthesized, and the specific sequences are shown in Table 2.
Based on the amino acid sequence of the Sema3A truncated protein polypeptide in Table 2, a cell-penetrating peptide (with the sequence YGRKKKRRQRRR) is introduced, and the cell-penetrating peptide is connected with the Sema3A truncated protein polypeptide in Table 2 (the C end of the cell-penetrating peptide is coupled with the N end of the polypeptide) to form the 'cell-penetrating peptide-Sema 3A truncated protein polypeptide'. Is prepared by artificially synthesizing polypeptide.
TABLE 2 polypeptide sequence of the truncated protein Sema3A
The amino acid sequence of the truncated protein of Sema3A (SEQ ID NO. 29):
NYQNGKNNVPRLKLSYKEMLESNNVITFNGLANSSSYHTFLLDEERSRLYVGAKDHIFSFDLVNIKDFQKIVWPVSYTRRDECKWAGKDILKECANFIKVLKAYNQTHLYACGTGAFHPICTYIEIGHHPEDNIFKLENSHFENGRGKSPYDPKLLTASLLIDGELYSGTAADFMGRDFAIFRTLGHHHPIRTEQHDSRWLNDPKFISAHLISESDNPEDDKVYFFFRENAIDGEHSGKATHARIGQICKNDFGGHRSLVNKWTTFLKARLICSVPGPNGIDTHFDELQDVFLMNFKDPKNPVVYGVFTTSSNIFKGSAVCMYSMSDVRRVFLGPYAHRDGPNYQWVPYQGRVPYPRPGTCPSKTFGGFDSTKDLPDDVITFARSHPAMYNPVFPMNNRPIVIKTDVNYQFTQIVVDRVDAEDGQYDVMFIGTDVGTVLKVVSIPKETWYDLEEVLLEEMTVFREPTAISAMELSTKQQQLYIGSTAGVAQLPLHRCDIYGKACAECCLARDPYCAWDGSACSRYFPTAKRRTRRQDIRNGDPLTHCSDLHHDNHHGHSPEERIIYGVENSSTFLECSPKSQRALVYWQFQRRNEERKEEIRVDDHIIRTDQGLLLRSLQQKDSGNYLCHAVEHGFIQTLLKVTLEVIDT。
example 2: screening of Sema3A truncated protein Polypeptides
The cell-penetrating peptide-Sema 3A truncated protein polypeptide was inoculated into human ovarian cancer cell lines (SKOV 3, HO-8910PM, HO-8910LM, OVCA429 and OVCA420, from ATCC cell bank) for tumor suppression test (MTT test).
1 taking human ovarian carcinoma cells (SKOV 3, HO-8910PM, HO-8910LM, OVCA429 and OVCA 420) in logarithmic growth phase, digesting the cells with 0.25% trypsin at 37 deg.C, inoculating 5000 cells per well into 96 micro-well plate, 200 μ l per well volume, and 5% CO at 37 deg.C 2 Culturing in incubator for 6-7 hr.
2 respectively taking the cell-penetrating peptide-Sema 3A truncated protein polypeptide mother liquor, adding 800 μ l of serum-free RPMI1640 culture medium to 1ml to ensure that the drug concentration is 50 μ M, adding 200 μ l of the drug-free drug into each well, using the drug-free drug as a negative control group, using 6 μ M taxol as a positive control group (5 duplicate wells are arranged for each drug concentration), and performing 5 percent CO analysis at 37 DEG C 2 The treatment was carried out under the conditions for 48 hours.
3 the plate was removed, 20. Mu.l of MTT solution (5 mg/ml in PBS) was added to each well, incubation was continued for 4 hours, the culture was terminated, the culture supernatant in the wells was carefully discarded, 150. Mu.l of DMSO was added to each well to dissolve MTT formazan precipitate, the solution was shaken at a low speed for about 10 minutes by a micro-shaker, and the absorbance (A) at a wavelength of 570nm was measured by an enzyme-linked immunosorbent assay (ELISA) detector after the crystals were completely dissolved.
4 the tumor cell growth inhibition rate can be calculated according to the following formula: growth inhibition ratio of tumor cells (%) = [ (negative control well a value-experimental well a value)/negative control well a value ] × 100%. The results are shown in Table 3, and the Sema3A truncated protein polypeptides 10, 16, 20 and 26 all have higher inhibition rates in 5 cell lines, while other polypeptides have poorer inhibition rates or have higher and lower inhibition rates in some cell lines.
TABLE 3 results of inhibition test of each polypeptide in human ovarian cancer cells
Example 3: combination therapy with Sema3A truncated protein polypeptides
The specific MTT assay method for 5 human ovarian cancer cells is shown in example 2 by performing different permutation and combination on 4 polypeptides (Sema 3A truncated protein polypeptides 10, 16, 20 and 26) screened in example 2 (the total drug concentration in each combination is 50 μ M, and the dosage of different drugs in the combination is equally divided in equal proportion). The results show (table 4) that the combination treatment is more effective than the monotherapy, and the more the polypeptide species, the better the effect.
TABLE 4 results of inhibition test of human ovarian cancer cells by different combination polypeptides
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such modifications are intended to be included in the scope of the present invention.
Claims (7)
1. A polypeptide for inhibiting human ovarian cancer cells, wherein the polypeptide is derived from a truncated protein of Sema3A, and the polypeptide derived from the truncated protein of Sema3A is coupled with a cell-penetrating peptide to form a cell-penetrating peptide-truncated protein of Sema3A polypeptide; the said polypeptide of truncated protein of Sema3A includes 4 polypeptides, said 4 polypeptides are polypeptide of truncated protein of Sema3A 10, polypeptide of truncated protein of Sema3A 16, polypeptide of truncated protein of Sema3A 20, polypeptide of truncated protein of Sema3A 26 respectively; the amino acid sequences of the Sema3A truncated protein polypeptide 10, the Sema3A truncated protein polypeptide 16, the Sema3A truncated protein polypeptide 20 and the Sema3A truncated protein polypeptide 26 are respectively shown as SEQ ID NO.10, SEQ ID NO.16, SEQ ID NO.20 and SEQ ID NO. 26.
2. The polypeptide of claim 1, wherein said truncated Sema3A protein has the amino acid sequence set forth in SEQ ID No. 29.
3. The polypeptide of claim 1, wherein the amino acid sequence of the cell-penetrating peptide is YGRKKKRRQRRR.
4. The polypeptide of claim 3, wherein the C-terminus of the cell-penetrating peptide is coupled to the N-terminus of the polypeptide of the truncated Sema3A protein.
5. A medicament for inhibiting ovarian cancer cells, which comprises any one or any two or any three or four of the polypeptides of the transmembrane peptide-Sema 3A truncated protein of claim 1.
6. The agent of claim 5, wherein the total concentration of the polypeptides in the agent is 50 μ M.
7. Use of the polypeptide of claim 1 for inhibiting human ovarian cancer cells in the preparation of a medicament for treating epithelial ovarian cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310146388.5A CN115947817A (en) | 2023-02-22 | 2023-02-22 | Tumor-related polypeptide and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310146388.5A CN115947817A (en) | 2023-02-22 | 2023-02-22 | Tumor-related polypeptide and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115947817A true CN115947817A (en) | 2023-04-11 |
Family
ID=87287906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310146388.5A Pending CN115947817A (en) | 2023-02-22 | 2023-02-22 | Tumor-related polypeptide and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115947817A (en) |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001038491A2 (en) * | 1999-11-08 | 2001-05-31 | The General Hospital Corporation | Novel semaphorin domains |
| CA2492655A1 (en) * | 2002-04-19 | 2003-10-30 | Genevieve Rougon | Peptides capable of inducing attraction to the axonal growth and their use for treating neurodegenerative diseases |
| CN102238965A (en) * | 2008-12-03 | 2011-11-09 | 优普音芬尼迪株式会社 | Selective anticancer chimeric peptide |
| WO2013129620A1 (en) * | 2012-02-28 | 2013-09-06 | 国立大学法人東京医科歯科大学 | Composition for increasing bone mass |
| US20150211021A1 (en) * | 2013-12-12 | 2015-07-30 | Life Technologies Corporation | Membrane-penetrating peptides to enhance transfection and compositions and methods for using same |
| CN107353333A (en) * | 2017-06-29 | 2017-11-17 | 西安交通大学医学院第附属医院 | A kind of bone protectiveness molecule Semaphorine3A and its pharmacy application |
| CN107810192A (en) * | 2015-02-23 | 2018-03-16 | 海鸥治疗简易股份公司 | Non-natural brain signal albumen 3 and its medical usage |
| CN110721308A (en) * | 2019-11-19 | 2020-01-24 | 四川大学华西医院 | Pharmaceutical compound preparation for treating osteoarthritis and preparation method thereof |
| CN112641928A (en) * | 2019-10-11 | 2021-04-13 | 田中纯美 | Polypeptide for angiogenesis and lymphangiogenesis related diseases and application thereof |
| WO2021245670A1 (en) * | 2020-06-04 | 2021-12-09 | Medical Research & Development Fund for Health Services Bnai Zion Medical Center | Modified semaphorin 3a, compositions comprising the same and uses thereof |
| US20220251193A1 (en) * | 2019-06-27 | 2022-08-11 | Ramot At Tel-Aviv University Ltd. | Semaphorin 3a antibodies and uses thereof |
-
2023
- 2023-02-22 CN CN202310146388.5A patent/CN115947817A/en active Pending
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001038491A2 (en) * | 1999-11-08 | 2001-05-31 | The General Hospital Corporation | Novel semaphorin domains |
| CA2492655A1 (en) * | 2002-04-19 | 2003-10-30 | Genevieve Rougon | Peptides capable of inducing attraction to the axonal growth and their use for treating neurodegenerative diseases |
| CN102238965A (en) * | 2008-12-03 | 2011-11-09 | 优普音芬尼迪株式会社 | Selective anticancer chimeric peptide |
| WO2013129620A1 (en) * | 2012-02-28 | 2013-09-06 | 国立大学法人東京医科歯科大学 | Composition for increasing bone mass |
| US20150211021A1 (en) * | 2013-12-12 | 2015-07-30 | Life Technologies Corporation | Membrane-penetrating peptides to enhance transfection and compositions and methods for using same |
| CN107810192A (en) * | 2015-02-23 | 2018-03-16 | 海鸥治疗简易股份公司 | Non-natural brain signal albumen 3 and its medical usage |
| CN107353333A (en) * | 2017-06-29 | 2017-11-17 | 西安交通大学医学院第附属医院 | A kind of bone protectiveness molecule Semaphorine3A and its pharmacy application |
| US20220251193A1 (en) * | 2019-06-27 | 2022-08-11 | Ramot At Tel-Aviv University Ltd. | Semaphorin 3a antibodies and uses thereof |
| CN112641928A (en) * | 2019-10-11 | 2021-04-13 | 田中纯美 | Polypeptide for angiogenesis and lymphangiogenesis related diseases and application thereof |
| CN110721308A (en) * | 2019-11-19 | 2020-01-24 | 四川大学华西医院 | Pharmaceutical compound preparation for treating osteoarthritis and preparation method thereof |
| WO2021245670A1 (en) * | 2020-06-04 | 2021-12-09 | Medical Research & Development Fund for Health Services Bnai Zion Medical Center | Modified semaphorin 3a, compositions comprising the same and uses thereof |
Non-Patent Citations (5)
| Title |
|---|
| ANAT SHIRVA ET AL.: "Induction of neuronal apoptosis by Semaphorin3A-derived peptide", 《MOLECULAR BRAIN RESEARCH》, 31 December 2000 (2000-12-31), pages 81 - 93 * |
| HANAE UEYAMA ET AL.: "Semaphorin 3A lytic hybrid peptide binding to neuropilin-1 as a novel anti-cancer agent in pancreatic cancer", 《BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS》, 14 September 2011 (2011-09-14), pages 60 - 66 * |
| KAEKO KAMIDE ET AL.: "Isolation of novel cell-penetrating peptides from a random peptide library using in vitro virus and their modifications", 《INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE》, 1 January 2010 (2010-01-01), pages 41 - 51, XP055370739, DOI: 10.3892/ijmm_00000311 * |
| MASAYUKI KOHNO ET AL.: "nhibition of Neurite Outgrowth by a Neuropilin-1 Binding Peptide Derived from Semaphorin 3A", 《INT J PEPT RES》, 31 December 2014 (2014-12-31), pages 153 - 160 * |
| 佚名: "semaphorin-3A isoform X2 [Pan troglodytes]", 《NCBI》, 20 March 2018 (2018-03-20), pages 1 - 2 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003516731A (en) | Human FGF-21 gene and gene expression product | |
| JP2003530325A (en) | Diagnostics and agents for the investigation of cell surface proteomes of tumors and inflammatory cells, and the treatment of tumor and inflammatory diseases, preferably with the aid of specific chemokine receptor analysis and chemokine receptor / ligand interactions | |
| JP2001508643A (en) | Peptides with antiproliferative properties | |
| CN104177500B (en) | A kind of tumour putrescence gene related apoptosis ligand fusion protein and its preparation method and purposes | |
| CN115947817A (en) | Tumor-related polypeptide and preparation method and application thereof | |
| US7893246B2 (en) | Sirna capable of inhibiting the expression of an oncogene involved in cervical cancer | |
| EP1355944B1 (en) | Rtvp based compositions and methods for the treatment of prostate cancer | |
| EP1743940B1 (en) | Cardioinhibitory/ antihypertensive novel endogenous physiologically active peptide | |
| CN109627289B (en) | BH3 polypeptide analogue with anti-tumor activity | |
| CN116407620A (en) | Use of recombinant type III humanized collagen in breast cancer treatment | |
| EP1335024A1 (en) | Antibody inhibiting vplf activity | |
| WO2018181390A1 (en) | Antitumor peptide having pd-1 signal sequence and utilization thereof | |
| CN114437178B (en) | BIDBH3 mimic peptide compound taking PTP1B as target point, and preparation method and application thereof | |
| US20200407412A1 (en) | Antitumor peptide and use thereof | |
| US5948883A (en) | Human CRM1 Protein | |
| CN106916211B (en) | Polypeptide inhibitor of MACC1 gene and application thereof | |
| CN116715761B (en) | Therapeutic monoclonal antibody and application thereof | |
| CN117756893A (en) | EGFR (epidermal growth factor receptor) inhibition polypeptide compound and preparation method and application thereof | |
| JP3385408B2 (en) | Novel protein and its antibody, and method for producing the new protein | |
| CN116621946B (en) | Application of polypeptide circ1946-109aa as esophageal squamous carcinoma prognosis marker | |
| CN113072633B (en) | CDH11 truncated variant and application thereof | |
| CN110330548B (en) | Anti-tumor polypeptide and application thereof in preparation of anti-tumor medicine | |
| CN106928325B (en) | Artificial polypeptide for enhancing killing sensitivity of liver cancer cells to CIK cells and biological product thereof | |
| CN107082800B (en) | Inhibitor of MACC1 gene and application thereof in resisting hepatocellular carcinoma invasion | |
| Yamada et al. | Structure, expression and function of mouse laminin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |